Arcturus Therapeutics Holdings (ARCT) Net Income towards Common Stockholders (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Net Income towards Common Stockholders of -$56.6 million for Q1 2026, down 94.78% on a QoQ basis from -$29.1 million in Q4 2025, and down 302.2% year-over-year from $28.0 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$56.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 302.2% year-over-year to -$56.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.3 million (down 58.92% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.74% from the prior year.
- Net Income towards Common Stockholders was -$56.6 million for Q1 2026 at Arcturus Therapeutics Holdings, down from -$29.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $118.6 million in Q4 2022 and bottomed at -$56.6 million in Q1 2026.
- A 5-year average of -$13.1 million and a median of -$17.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 413.74% — and 2026, when it sank 302.2%.
- Arcturus Therapeutics Holdings' Net Income towards Common Stockholders stood at $118.6 million in 2022, then plunged by 109.87% to -$11.7 million in 2023, then tumbled by 156.3% to -$30.0 million in 2024, then climbed by 3.13% to -$29.1 million in 2025, then slumped by 94.78% to -$56.6 million in 2026.
- Business Quant data shows ARCT's Net Income towards Common Stockholders at -$56.6 million in Q1 2026, -$29.1 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Arcturus Therapeutics Holdings | 165.13 Mn | -46.25 Mn | - | -56.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.61 Mn |
| Dec 31, 2025 | -29.07 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.17 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.23 Mn |
| Jun 30, 2023 | -52.57 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 118.64 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.27 Mn |
| Dec 31, 2021 | -37.82 Mn |
| Sep 30, 2021 | -61.28 Mn |
| Jun 30, 2021 | -61.69 Mn |